SNCA and Mental deterioration: For example, cognitive decline affects 70% of PD patients with pathogenic alpha-synuclein (SNCA) gene variants, while only 23% of Leucine-Rich Repeat Kinase 2 (LRRK2) carriers exhibit cognitive impairment (18).